Cardiovascular Diseases Clinical Trial
Official title:
Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)
The purpose of this study is to compare the effectiveness of aortic stent surgery versus exercise therapy in individuals with aortoiliac insufficiency.
BACKGROUND:
Peripheral arterial disease (PAD) is a major source of morbidity and mortality, particularly
in older individuals. Despite its high prevalence, clinicians often fail to diagnose PAD,
particularly in patients who do not have classic claudication symptoms. Even in those
individuals with documented PAD, cardiac risk factors are not often aggressively treated,
and only a minority of patients receive pharmacologic therapy with cilostazol. Although
there is a growing body of literature demonstrating the value of exercise rehabilitation in
individuals with peripheral vascular disease and claudication, exercise rehabilitation is
not often prescribed as supervised exercise rehabilitation for claudication, is not
reimbursed by Medicare, and is rarely covered by private insurance. Therefore, few
individuals with PAD and intermittent claudication have access to supervised exercise
rehabilitation.
The use of surgical intervention and stent placement to improve blood flow in patients who
do not have ischemic pain at rest or limb-threatening ischemia (Fontaine class III or IV)
remains controversial. There is data suggesting that patients with intermittent claudication
who have had revascularization with stents have improved exercise capacity and walking
times. However, the patients in the various studies often differ substantially in their
clinical characteristics, and a variety of techniques were employed, including balloon
angioplasty and stents, which makes it difficult to come to a definitive conclusion about
the relative efficacy of stenting to improve functional performance. Additionally, to our
knowledge, the combination of stent revascularization with supervised exercise
rehabilitation has not been studied.
DESIGN NARRATIVE:
The broad objective of the study is to optimize physical functioning, increase activity
levels, and reduce cardiovascular disease risk in older individuals with PAD. The specific
aim of the trial is to test the primary hypothesis that aortoiliac stenting/pharmacotherapy
improves maximum walking duration (MWD) better than supervised exercise
rehabilitation/exercise maintenance/pharmacotherapy for those with aortoiliac artery
obstruction at 6 months. Other aims are to compare these two treatment groups with two other
treatment groups, optimal medical care/pharmacotherapy and combined stent plus supervised
exercise rehabilitation, at 6 months, and to compare all 4 groups with regard to the
following variables: MWD change score at 18 months, changes in free-living daily activity
levels, patient-perceived quality of life (QoL), and cost-effectiveness. The study also will
perform exploratory analyses of demographic and biochemical risk factors for
atherosclerosis, including body mass index (BMI), blood pressure, lipid profile, hemoglobin
Alc (HgbAlc), fibrinogen, and C-reactive protein. An estimated 252 patients (at up to 30
study sites) with aortoiliac insufficiency and intermittent claudication will be randomly
divided into four groups: optimal medical care/pharmacotherapy, supervised exercise
rehabilitation/maintenance/pharmacotherapy, stent/pharmacotherapy, and stent/supervised
exercise rehabilitation/pharmacotherapy. Recruitment will be performed over 28 months and
patients will be followed for 18 months; the total study duration will be 5 years.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|